Identification of Circulating MicroRNAs as Potential Biomarkers for Detecting Acute Myeloid Leukemia

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Zhi, Feng ^a   Cao, Xiangshan ^a   Xie, Xiaobao ^a   Wang, Biao ^a   Dong, Weimin ^a   Gu, Weiying ^a   Ling, Yun ^a   Wang, Rong ^a   Yang, Yilin ^a   Liu, Yan ^a  

^a THE THIRD AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 10A 5P; MICRORNA 129 5P; MICRORNA 155 5P; MICRORNA 181B 5P; MICRORNA 320D; MICRORNA 93 5P; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; BLOOD SAMPLING; CANCER DIAGNOSIS; CLUSTER ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; RNA ANALYSIS; VALIDATION PROCESS;

ADULT; AGED; EARLY DETECTION OF CANCER; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; GENOME, HUMAN; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MICRORNAS; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84874268409     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056718     Document Type: Article

References (53)

1. Tefferi A, Thiele J, Vardiman JW, (2009) The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer 115: 3842-3847.
2. Gregory TK, Wald D, Chen Y, Vermaat JM, Xiong Y, et al. (2009) Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics. J Hematol Oncol 2: 23.
3. Bartel DP, (2009) MicroRNAs: target recognition and regulatory functions. Cell 136: 215-233.
4. Marcucci G, Radmacher MD, Maharry K, Mrozek K, Ruppert AS, et al. (2008) MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med 358: 1919-1928.
5. Garzon R, Volinia S, Liu CG, Fernandez-Cymering C, Palumbo T, et al. (2008) MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 111: 3183-3189.
6. Jongen-Lavrencic M, Sun SM, Dijkstra MK, Valk PJ, Lowenberg B, (2008) MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood 111: 5078-5085.
7. Chen X, Ba Y, Ma L, Cai X, Yin Y, et al. (2008) Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18: 997-1006.
8. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, et al. (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 105: 10513-10518.
9. Sun SM, Rockova V, Bullinger L, Dijkstra MK, Dohner H, et al. (2012) The prognostic relevance of miR-212 expression with survival in cytogenetically and molecularly heterogeneous AML. Leukemia.
10. Li Z, Huang H, Li Y, Jiang X, Chen P, et al. (2012) Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML. Blood 119: 2314-2324.
11. Wang F, Wang XS, Yang GH, Zhai PF, Xiao Z, et al. (2012) miR-29a and miR-142-3p downregulation and diagnostic implication in human acute myeloid leukemia. Mol Biol Rep 39: 2713-2722.
12. Zen K, Zhang CY, (2012) Circulating microRNAs: a novel class of biomarkers to diagnose and monitor human cancers. Med Res Rev 32: 326-348.
13. Kohavi R (1995) A study of cross-validation and bootstrap for accuracy estimation and model selection. Proceedings of the 14th international joint conference on Artificial intelligence- Volume 2. Montreal, Quebec, Canada: Morgan Kaufmann Publishers Inc. 1137-1143.
14. Hu Z, Chen X, Zhao Y, Tian T, Jin G, et al. (2010) Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol 28: 1721-1726.
15. Zhang C, Wang C, Chen X, Yang C, Li K, et al. (2010) Expression profile of microRNAs in serum: a fingerprint for esophageal squamous cell carcinoma. Clin Chem 56: 1871-1879.
16. Marcucci G, Mrozek K, Radmacher MD, Garzon R, Bloomfield CD, (2011) The prognostic and functional role of microRNAs in acute myeloid leukemia. Blood 117: 1121-1129.
17. Bryant A, Palma CA, Jayaswal V, Yang YW, Lutherborrow M, et al. (2012) miR-10a is aberrantly overexpressed in Nucleophosmin1 mutated acute myeloid leukaemia and its suppression induces cell death. Mol Cancer 11: 8.
18. Ovcharenko D, Stolzel F, Poitz D, Fierro F, Schaich M, et al. (2011) miR-10a overexpression is associated with NPM1 mutations and MDM4 downregulation in intermediate-risk acute myeloid leukemia. Exp Hematol 39: 1030-1042 e1037.
19. Zhu YD, Wang L, Sun C, Fan L, Zhu DX, et al. (2012) Distinctive microRNA signature is associated with the diagnosis and prognosis of acute leukemia. Med Oncol 29: 2323-2331.
20. Faraoni I, Laterza S, Ardiri D, Ciardi C, Fazi F, et al. (2012) MiR-424 and miR-155 deregulated expression in cytogenetically normal acute myeloid leukaemia: correlation with NPM1 and FLT3 mutation status. J Hematol Oncol 5: 26.
21. Whitman SP, Maharry K, Radmacher MD, Becker H, Mrozek K, et al. (2010) FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood 116: 3622-3626.
22. Garzon R, Garofalo M, Martelli MP, Briesewitz R, Wang L, et al. (2008) Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci U S A 105: 3945-3950.
23. O'Connell RM, Rao DS, Chaudhuri AA, Boldin MP, Taganov KD, et al. (2008) Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J Exp Med 205: 585-594.
24. Cao P, Zhou L, Zhang J, Zheng F, Wang H, et al. (2012) Comprehensive expression profiling of microRNAs in laryngeal squamous cell carcinoma. Head Neck.
25. Fu X, Tian J, Zhang L, Chen Y, Hao Q, (2012) Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells. FEBS Lett 586: 1279-1286.
26. Fang L, Deng Z, Shatseva T, Yang J, Peng C, et al. (2011) MicroRNA miR-93 promotes tumor growth and angiogenesis by targeting integrin-beta8. Oncogene 30: 806-821.
27. Zhang H, Li W, Nan F, Ren F, Wang H, et al. (2011) MicroRNA expression profile of colon cancer stem-like cells in HT29 adenocarcinoma cell line. Biochem Biophys Res Commun 404: 273-278.
28. Dyrskjot L, Ostenfeld MS, Bramsen JB, Silahtaroglu AN, Lamy P, et al. (2009) Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res 69: 4851-4860.
29. Wu J, Qian J, Li C, Kwok L, Cheng F, et al. (2010) miR-129 regulates cell proliferation by downregulating Cdk6 expression. Cell Cycle 9: 1809-1818.
30. Liu Y, Hei Y, Shu Q, Dong J, Gao Y, et al. (2012) VCP/p97, down-regulated by microRNA-129-5p, could regulate the progression of hepatocellular carcinoma. PLoS One 7: e35800.
31. Liao R, Sun J, Zhang L, Lou G, Chen M, et al. (2008) MicroRNAs play a role in the development of human hematopoietic stem cells. J Cell Biochem 104: 805-817.
32. Chen L, Yang Q, Kong WQ, Liu T, Liu M, et al. (2012) MicroRNA-181b targets cAMP responsive element binding protein 1 in gastric adenocarcinomas. IUBMB Life 64: 628-635.
33. Wang B, Li W, Guo K, Xiao Y, Wang Y, et al. (2012) miR-181b promotes hepatic stellate cells proliferation by targeting p27 and is elevated in the serum of cirrhosis patients. Biochem Biophys Res Commun 421: 4-8.
34. Lu Y, Roy S, Nuovo G, Ramaswamy B, Miller T, et al. (2011) Anti-microRNA-222 (anti-miR-222) and-181B suppress growth of tamoxifen-resistant xenografts in mouse by targeting TIMP3 protein and modulating mitogenic signal. J Biol Chem 286: 42292-42302.
35. Wang B, Hsu SH, Majumder S, Kutay H, Huang W, et al. (2010) TGFbeta-mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3. Oncogene 29: 1787-1797.
36. Zhu DX, Zhu W, Fang C, Fan L, Zou ZJ, et al. (2012) miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes. Carcinogenesis 33: 1294-1301.
37. Visone R, Veronese A, Rassenti LZ, Balatti V, Pearl DK, et al. (2011) miR-181b is a biomarker of disease progression in chronic lymphocytic leukemia. Blood 118: 3072-3079.
38. Cui Y, Han Z, Hu Y, Song G, Hao C, et al. (2012) MicroRNA-181b and microRNA-9 mediate arsenic-induced angiogenesis via NRP1. J Cell Physiol 227: 772-783.
39. Sun X, Icli B, Wara AK, Belkin N, He S, et al. (2012) MicroRNA-181b regulates NF-kappaB-mediated vascular inflammation. J Clin Invest 122: 1973-1990.
40. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, et al. (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 103: 2257-2261.
41. Eis PS, Tam W, Sun L, Chadburn A, Li Z, et al. (2005) Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci U S A 102: 3627-3632.
42. Lowery AJ, Miller N, McNeill RE, Kerin MJ, (2008) MicroRNAs as prognostic indicators and therapeutic targets: potential effect on breast cancer management. Clin Cancer Res 14: 360-365.
43. Campayo M, Navarro A, Vinolas N, Diaz T, Tejero R, et al. (2012) Low miR-145 and high miR-367 are associated with unfavorable prognosis in resected NSCLC. Eur Respir J.
44. Chen X, Hu Z, Wang W, Ba Y, Ma L, et al. (2012) Identification of ten serum microRNAs from a genome-wide serum microRNA expression profile as novel noninvasive biomarkers for nonsmall cell lung cancer diagnosis. Int J Cancer 130: 1620-1628.
45. Ohshima K, Inoue K, Fujiwara A, Hatakeyama K, Kanto K, et al. (2010) Let-7 microRNA family is selectively secreted into the extracellular environment via exosomes in a metastatic gastric cancer cell line. PLoS One 5: e13247.
46. Smith ML, Hills RK, Grimwade D, (2011) Independent prognostic variables in acute myeloid leukaemia. Blood Rev 25: 39-51.
47. Xiong Y, Li Z, Ji M, Tan AC, Bemis J, et al. (2011) MIR29B regulates expression of MLLT11 (AF1Q), an MLL fusion partner, and low MIR29B expression associates with adverse cytogenetics and poor overall survival in AML. Br J Haematol 153: 753-757.
48. Blum W, Garzon R, Klisovic RB, Schwind S, Walker A, et al. (2010) Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci U S A 107: 7473-7478.
49. Marcucci G, Maharry K, Radmacher MD, Mrozek K, Vukosavljevic T, et al. (2008) Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. J Clin Oncol 26: 5078-5087.
50. Schwind S, Maharry K, Radmacher MD, Mrozek K, Holland KB, et al. (2010) Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 28: 5257-5264.
51. Hafner M, Landgraf P, Ludwig J, Rice A, Ojo T, et al. (2008) Identification of microRNAs and other small regulatory RNAs using cDNA library sequencing. Methods 44: 3-12.
52. Griffiths-Jones S, (2004) The microRNA Registry. Nucleic Acids Res 32: D109-111.
53. Liu R, Zhang C, Hu Z, Li G, Wang C, et al. (2011) A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur J Cancer 47: 784-791.